Cellular Proteostasis in Neurodegeneration.
DOI: 10.1007/s12035-018-1334-zPMID: 30182337
Clinical implications and electrochemical biosensing of monoamine neurotransmitters in body fluids, in vitro, in vivo, and ex vivo models.
DOI: 10.1016/j.bios.2018.09.002PMID: 30212666
Pedunculopontine nucleus: An integrative view with implications on Deep Brain Stimulation.
DOI: 10.1016/j.nbd.2018.08.015PMID: 30189263
The Sources of Reactive Oxygen Species and Its Possible Role in the Pathogenesis of Parkinson's Disease.
DOI: 10.1155/2018/9163040PMID: 30245802
Clinical Review Report: Levodopa/Carbidopa (Duodopa): (Abbvie Corporation): Indication: For the treatment of patients with advanced levodopa-responsive Parkinson’s disease who do not have satisfactory control of severe, debilitating motor fluctuations and hyper-/dyskinesia despite optimized treatment with available combinations of Parkinson’s medicinal products, and, for whom the benefits of this treatment may outweigh the risks associated with the insertion and long-term use of the percutaneous endoscopic gastrostomy-jejunostomy (PEG-J) tube required for administration
PMID: 30958666
Pharmacoeconomic Review Report: Levodopa/Carbidopa (Duodopa): (Abbvie Corporation): Indication: For the treatment of patients with advanced levodopa-responsive Parkinson’s disease who do not have satisfactory control of severe, debilitating motor fluctuations and hyper-/dyskinesia despite optimized treatment with available combinations of Parkinson’s medicinal products, and, for whom the benefits of this treatment may outweigh the risks associated with the insertion and long-term use of the percutaneous endoscopic gastrostomy-jejunostomy (PEG-J) tube required for administration
PMID: 30942993
Biomarkers for detection, prognosis and therapeutic assessment of neurological disorders.
DOI: 10.1515/revneuro-2017-0097PMID: 29466244
Neurological and psychiatric disorders in psoriasis.
DOI: 10.1515/revneuro-2017-0108PMID: 29509545
Prognostic factors of functional outcome after hip fracture surgery: a systematic review.
DOI: 10.1093/ageing/afy057PMID: 29668839
Pimavanserin for Psychotic Symptoms in People With Parkinsonism: A Second Chart Review.
DOI: 10.1097/wnf.0000000000000296PMID: 30004964
Therapeutic Management of the Overlapping Syndromes of Atypical Parkinsonism.
DOI: 10.1007/s40263-018-0551-3PMID: 30051337
Degenerative or Debilitative Neurologic Syndromes.
DOI: 10.1016/j.cnur.2018.05.002PMID: 30100009
Kayıtlar bilimsel kaynaklardan alınır. Bibliyografik kayıt sayısı, Türkçe çeviri veya editoryal onay sayısı değildir.
NeuralCipher